We are live on
!
Find out more
FLAM
First Light Asset Management Portfolio holdings
AUM
$1.12B
1-Year Est. Return
114.45%
This Fund
S&P 500
This Quarter
Est. Return
+15%
1 Year Est. Return
+114.45%
3 Year Est. Return
+266.49%
5 Year Est. Return
+454.92%
10 Year Est. Return
+8,470.94%
AUM
$298M
AUM Growth
+$36.1M
(+14%)
Cap. Flow
-$1.63M
Cap. Flow
% of AUM
-0.55%
Top 10 Holdings %
Top 10 Hldgs %
50.06%
Holding
56
New
4
Increased
19
Reduced
20
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Omnicell
OMCL
|
+$6M |
| 2 |
NVRO
NEVRO CORP.
NVRO
|
+$4.76M |
| 3 |
Nektar Therapeutics
NKTR
|
+$4.75M |
| 4 |
SHPG
Shire pic
SHPG
|
+$2.4M |
| 5 |
ENTL
Entellus Medical, Inc. Common Stock
ENTL
|
+$1.46M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
XENT
Intersect ENT, Inc
XENT
|
+$8.92M |
| 2 |
ENZ
Enzo Biochem, Inc.
ENZ
|
+$6.7M |
| 3 |
HealthStream
HSTM
|
+$3.4M |
| 4 |
LHCG
LHC Group LLC
LHCG
|
+$2.04M |
| 5 |
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
|
+$1.46M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 74.97% |
| 2 | Energy | 2.09% |
| 3 | Communication Services | 1.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AKRX
1
DELISTED
Akorn Inc
AKRX
| $24.6M | 8.24% |
732,462
-43,129
| -6% | -$1.4M |
|
2
NeoGenomics
NEO
$1.96B
| $24M | 8.05% |
2,679,271
+25,617
| +1% | +$203K |
|
3
AtriCure
ATRC
$1.92B
| $23.3M | 7.8% |
958,858
+2,400
| +0.3% | +$51K |
|
|
IMMU
4
DELISTED
Immunomedics Inc
IMMU
| $18.1M | 6.07% |
2,048,643
-47,852
| -2% | -$336K |
|
|
5
Omnicell
OMCL
$1.61B
| $12M | 4.02% |
278,294
+144,471
| +108% | +$6M |
|
|
SHPG
6
DELISTED
Shire pic
SHPG
| $11.5M | 3.85% |
69,519
+13,728
| +25% | +$2.4M |
|
|
7
Nektar Therapeutics
NKTR
$2.39B
| $9.19M | 3.08% |
31,346
+16,451
| +110% | +$4.75M |
|
8
Harvard Bioscience
HBIO
$27.5M
| $9.11M | 3.06% |
357,220
+36,771
| +11% | +$910K |
|
|
OXFD
9
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $8.82M | 2.96% |
524,509
-97,729
| -16% | -$1.46M |
|
|
TLGT
10
DELISTED
Teligent, Inc
TLGT
| $8.68M | 2.91% |
94,846
-92
| -0.1% | -$7.83K |
|
|
ENTL
11
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
| $8.49M | 2.85% |
512,416
+104,919
| +26% | +$1.46M |
|
|
SPNC
12
DELISTED
Spectranetics Corp
SPNC
| $8.36M | 2.8% |
217,637
+35,481
| +19% | +$1.02M |
|
|
XENT
13
DELISTED
Intersect ENT, Inc
XENT
| $7.65M | 2.57% |
273,645
-393,859
| -59% | -$8.92M |
|
14
Ligand Pharmaceuticals
LGND
$5.76B
| $7.6M | 2.55% |
100,385
-27
| -0% | -$1.89K |
|
|
SAGE
15
DELISTED
Sage Therapeutics
SAGE
| $7.39M | 2.48% |
92,761
-704
| -0.8% | -$50.9K |
|
|
KTWO
16
DELISTED
K2M Group Holdings, Inc
KTWO
| $6.61M | 2.22% |
271,495
-203
| -0.1% | -$4.51K |
|
17
Veracyte
VCYT
$3.7B
| $6.29M | 2.11% |
754,560
+33,682
| +5% | +$275K |
|
|
LHCG
18
DELISTED
LHC Group LLC
LHCG
| $6.24M | 2.09% |
91,917
-34,206
| -27% | -$2.04M |
|
|
AMED
19
DELISTED
Amedisys
AMED
| $5.81M | 1.95% |
92,535
-14
| -0% | -$815 |
|
|
MODN
20
DELISTED
MODEL N, INC.
MODN
| $5.63M | 1.89% |
423,211
+2,461
| +0.6% | +$29.4K |
|
21
Halozyme
HALO
$9.79B
| $5.34M | 1.79% |
416,579
+1,968
| +0.5% | +$26.3K |
|
|
MDCO
22
DELISTED
Medicines Co
MDCO
| $5.27M | 1.77% |
138,543
+1,804
| +1% | +$80.3K |
|
23
Heron Therapeutics
HRTX
$93.9M
| $5.09M | 1.71% |
367,390
+3,701
| +1% | +$53.6K |
|
|
24
HealthStream
HSTM
$819M
| $4.9M | 1.64% |
186,044
-123,887
| -40% | -$3.4M |
|
|
ARRY
25
DELISTED
Array Biopharma Inc
ARRY
| $4.79M | 1.61% |
571,629
+5,297
| +0.9% | +$43.3K |
|
Similar funds
AIM
MTCM
CNC
C
RIM
CT
SL
HH
First Light Asset Management's Q2 2017 Portfolio in Review
As of Q2 2017, First Light Asset Management held 56 positions worth $298M, up 14% from $262M the previous quarter. Its ten largest holdings account for 50% of the portfolio.
First Light Asset Management's Q2 2017 filing shows 4 new, 19 increased, 20 reduced and 1 closed positions. Its largest new stake was NEVRO CORP.: 59,358 shares worth $4.42M. The largest sale was Intersect ENT, Inc, an estimated $8.92M.
By sector, the portfolio is most concentrated in Healthcare at 75% of assets, up from 74% a quarter earlier, followed by Energy and Communication Services.
- First Light Asset Management's largest Q2 2017 buy was NEVRO CORP.: 59,358 shares worth $4.42M.
- First Light Asset Management added most to Omnicell in Q2 2017, an estimated $6M increase.
- First Light Asset Management's biggest Q2 2017 reduction was Intersect ENT, Inc, cutting an estimated $8.92M.
- First Light Asset Management fully exited Chembio diagnostics, Inc. in Q2 2017, selling an estimated $294K.
- First Light Asset Management's ten largest holdings make up 50% of its $298M portfolio in Q2 2017.
- First Light Asset Management opened 4 new positions and closed 1 in Q2 2017.
- First Light Asset Management's portfolio value rose 14% quarter-over-quarter to $298M.
Based on First Light Asset Management's 13F filing for Q2 2017, filed 14 Aug 2017.